Polycyclo Ring System Patents (Class 562/466)
  • Patent number: 10478410
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: November 19, 2019
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Patent number: 10322099
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 18, 2019
    Assignee: UNITED THERAPEUTICS CORPORATION
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Patent number: 10321695
    Abstract: A composition includes hesperdin and/or a Lamiaceae extract wherein a majority of the volatile components have been removed from the Lamiaceae extract. A method for applying the composition to a food such as meat, fish or poultry, including processed and fresh or unprocessed meat, poultry and fish is also provided.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: June 18, 2019
    Assignee: NATUREX S.A.
    Inventors: Simona Birtic, Mélanie Marie-Paule Patricia Heudre, François-Xavier Henri Pierre, Xavier Pierre François Mesnier, Anne Passemard, Antoine Charles Bily, Marc Roller
  • Patent number: 10226066
    Abstract: Provided are smoking products and methods of preparing smoking products that include tobacco and a deflavored rosemary or a heat-treated rosemary. The deflavored and/or heat-treated rosemary may have been previously heated at a temperature and a time sufficient to reduce or remove flavorant components compared to the use of untreated rosemary. The heated rosemary may include one or more pentacyclic triterpenoid acids such as betulinic, betul-18-enoic, oleanolic, and ursolic acids.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: March 12, 2019
    Assignee: R.J. REYNOLDS TOBACCO COMPANY
    Inventors: Serban C. Moldoveanu, Wayne Allen Scott
  • Patent number: 9988334
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 5, 2018
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay Sharma, Sanmin Yang, Yi Zhang
  • Patent number: 9701611
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: July 11, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay Sharma, Sanmin Yang, Yi Zhang
  • Patent number: 9604901
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: March 28, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Patent number: 9593066
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: March 14, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Patent number: 9278902
    Abstract: Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9±0.2°, 6.5±0.2°, 12.6±0.2°, 13.1±0.2° and 20.6±0.2°.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: March 8, 2016
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Zhijun Tang, Yubin Liu, Bingming He, Jun Yang, Xiaoming Ji
  • Patent number: 9278903
    Abstract: Provided are a crystal form A of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form A has characteristic peaks at the following diffraction angles: 2.9±0.2°, 13.6±0.2°, 17.3±0.2° and 18.6±0.2°.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: March 8, 2016
    Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.
    Inventors: Zhijun Tang, Yubin Liu, Bingming He, Jun Yang, Xiaoming Ji
  • Publication number: 20150148347
    Abstract: A compound of formula I, wherein the groups R1, R2, R3, X, m, and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 28, 2015
    Inventors: Iain LINGARD, Dieter HAMPRECHT
  • Publication number: 20150141662
    Abstract: The present invention relates to methods of preparing fused ring indeno compounds that involves reacting together a dienophile and a lactone compound, in the presence of a catalyst, and a carboxylic acid anhydride.
    Type: Application
    Filed: November 20, 2013
    Publication date: May 21, 2015
    Applicant: Transitions Optical, Inc.
    Inventors: Meng He, Massimiliano Tomasulo, Allison Greene, Anil Kumar
  • Publication number: 20150141506
    Abstract: Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the absolute stereochemistry and formula: In some cases R1 is leucine and R is selected from: OH, OCH3, OCH2CH3, OCH2CH2CH3, NH2, NHCH2CH2OH, NHCH3, N(CH3)2, NH(4-OH-3-benzoic acid).
    Type: Application
    Filed: May 23, 2013
    Publication date: May 21, 2015
    Inventors: Neil Frankish, Helen Sheridan
  • Publication number: 20150111891
    Abstract: The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.
    Type: Application
    Filed: January 3, 2013
    Publication date: April 23, 2015
    Applicant: Gilead Sciences, Inc.
    Inventors: Kerim Babaoglu, Gediminas Brizgys, Hongyan Guo, Paul Hrvatin, Eric Lansdon, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Yingmei Qi, Paul A. Roethle, Randall W. Vivian, Lianhong Xu, Hong Yang
  • Publication number: 20150105582
    Abstract: The present invention is directed to a novel method for preparing a synthetic intermediates for treprostinil. Also described are methods of preparing treprostinil comprising utilizing novel intermediates described herein as well as novel intermediates useful for synthesis prostacyclin derivatives, such as treprostinil.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh
  • Publication number: 20150094330
    Abstract: The invention provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.
    Type: Application
    Filed: September 26, 2014
    Publication date: April 2, 2015
    Inventors: Yariv Donde, Jeremiah H. Nguyen
  • Patent number: 8987334
    Abstract: The invention relates to the use of calixarenes for preventing or limiting the transfer of an actinide in the body from a site of skin contamination.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: March 24, 2015
    Assignee: Institut de Radioprotection et de Surete Nucleaire
    Inventors: Aurélie Spagnul, François Rebiere, Guillaume Phan, Céline Bouvier-Capely, Elias Fattal
  • Publication number: 20150064455
    Abstract: This invention relates to the direct grafting of a calixarene mostly onto the surface of a material, as well as to a grafting process, and certain calixarene intermediates useful for carrying the grafting process.
    Type: Application
    Filed: March 28, 2013
    Publication date: March 5, 2015
    Inventors: Ivan Jabin, Alice Mattiuzzi, Corlnne Lagrost, Philippe Hapiot, Olivia Reinaud
  • Publication number: 20150030980
    Abstract: A radiation-sensitive composition containing a resist compound having a high sensitivity, a high resolution, a high etching resistance, and a low outgas which forms a resist pattern with a good shape is described.
    Type: Application
    Filed: August 28, 2014
    Publication date: January 29, 2015
    Inventors: Masatoshi ECHIGO, Dai OGURO
  • Patent number: 8940930
    Abstract: The present invention is directed to a novel method for preparing a synthetic intermediates for treprostinil. Also described are methods of preparing treprostinil comprising utilizing novel intermediates described herein as well as novel intermediates useful for synthesis prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: January 27, 2015
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh
  • Publication number: 20150011637
    Abstract: Provided are a crystal form B of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form B has characteristic peaks at the following diffraction angles: 2.9±0.2°, 6.5±0.2°, 12.6±0.2°, 13.1±0.2° and 20.6±0.2°.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 8, 2015
    Inventors: Zhijun Tang, Yubin Liu, Bingming He, Jun Yang, Xiaoming Ji
  • Publication number: 20150005384
    Abstract: Provided are a crystal form A of a compound having the structure as represented by formula I, and preparation method and use thereof. The X-ray powder diffraction (XRPD) chart of the crystal form A has characteristic peaks at the following diffraction angles: 2.9±0.2°, 13.6±0.2°, 17.3±0.2° and 18.6±0.2°.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 1, 2015
    Inventors: Zhijun Tang, Yubin Liu, Bingming He, Jun Yang, Xiaoming Ji
  • Publication number: 20140343079
    Abstract: The invention provides compounds of formulae (I), (II), (III), and (IV): and salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and Alzheimer's disease.
    Type: Application
    Filed: September 13, 2012
    Publication date: November 20, 2014
    Applicants: Behalf of Arizona State University
    Inventors: Carl E. Wagner, Peter W. Jurutka, Pamela A. Marshall
  • Publication number: 20140309264
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Inventors: Matthias SCHAEFER, Josef PERNERSTORFER, Dieter KADEREIT, Hartmut STROBEL, Werngard CZECHTIZKY, L. Charlie CHEN, Alena SAFAROVA, Aleksandra WEICHSEL, Marcel PATEK
  • Publication number: 20140296270
    Abstract: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well as their derivatives. Methods of screening additional compounds for Stat3 inhibition activity and/or non-inhibition of Stat1 activity are also described herein.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 2, 2014
    Applicant: Baylor College of Medicine
    Inventors: David J. Tweardy, Xuejun Xu, Moses M. Kasembeli
  • Publication number: 20140275616
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay Sharma, Sanmin Yang, Yi Zhang
  • Publication number: 20140275262
    Abstract: There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Ken Phares, Michael Scannell
  • Publication number: 20140256730
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Application
    Filed: January 13, 2014
    Publication date: September 11, 2014
    Applicant: Corsair Pharma, Inc.
    Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Publication number: 20140231717
    Abstract: The present invention provides a compound that has high solubility in a highly polar solvent and is usefully usable for an application method using a highly polar solvent, the compound that can manufacture an electroluminescent device having high light-emitting efficiency. Specifically, the present invention provides a compound containing a structure represented by Formula (1): wherein: Ar1, Ar2, Ar3, and Ar4 each independently represent a divalent aromatic group optionally having substituent(s); Ar5 represents a monovalent aromatic group optionally having substituent(s); p and q each independently represent an integer of 0 or more; and R1 represents a given monovalent group.
    Type: Application
    Filed: October 11, 2012
    Publication date: August 21, 2014
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Ken Sakakibara, Masanobu Tanaka, Rui Ishikawa, Hideyuki Higashimura
  • Patent number: 8748657
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 10, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Patent number: 8722938
    Abstract: The present invention relates to arylated camphenes, processes for their preparation and uses thereof for the manufacture of medicaments for the treatment of diseases, disorders or conditions associated with, or benefiting from stimulation of CB2 receptors.
    Type: Grant
    Filed: November 18, 2010
    Date of Patent: May 13, 2014
    Inventors: Raphael Mechoulam, Lital Magid, Esther Shohami, Itai Bab
  • Publication number: 20140128466
    Abstract: Described are compounds of the structural formula (I): Also provided are pharmacologically acceptable isomers and salts of the compound of (I). The compounds are useful in the treatment of inflammatory bowel disease.
    Type: Application
    Filed: July 20, 2012
    Publication date: May 8, 2014
    Applicant: VENANTIUS LIMITED
    Inventors: Neil Frankish, Helen Sheridan
  • Publication number: 20140107194
    Abstract: Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted aryl, alkoxy, aryloxy, thiol, and optionally substituted amino, and wherein R1 is selected from one or more of the same or different of hydrogen, acetyl, optionally substituted alkyl, optionally substituted aryl, and an amino acid selected from leucine, valine, isoleucine, and glycine.
    Type: Application
    Filed: July 20, 2012
    Publication date: April 17, 2014
    Applicant: Venantius Limited
    Inventors: Neil Frankish, Helen Sheridan
  • Publication number: 20140039131
    Abstract: An electronic device that serves as a high-brightness electroluminescent device includes a layer containing a polymer compound having one or more structural units selected from a structural unit represented by formula (1) and a structural unit represented by formula (14) as a charge injection layer and/or a charge transport layer: wherein Ar1 and Ar2 represent certain fused polycyclic aromatic groups; R1, R2, R6 and R7 represent certain organic groups; m1, m2 and m6 represent an integer of 1 or more; m7 represents an integer of 0 or more; and when R1, R2, R6 and R7 are each plurally present, they each may be the same or different.
    Type: Application
    Filed: March 27, 2012
    Publication date: February 6, 2014
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Masanobu Tanaka, Rui Ishikawa, Norifumi Kobayashi, Ken Sakakibara, Hideyuki Higashimura
  • Publication number: 20140024856
    Abstract: Disclosed is a process for preparing a treprostinil salt. The process involves the step of dissolving treprostinil in a water-miscible organic solvent to form a treprostinil solution. The treprostinil solution is reacted with an aqueous basic solution containing an alkali metal cation to form treprostinil salt. Allowing crystallization of the treprostinil salt to take place, and then collecting the treprostinil salt formed.
    Type: Application
    Filed: December 22, 2011
    Publication date: January 23, 2014
    Applicant: ALPHORA RESEARCH INC.
    Inventors: Walter Giust, Fabio Souza, Jan Oudenes, Boris Gorin, Elena Bejan
  • Publication number: 20130345471
    Abstract: The compound according to Formula I is an intermediate in the synthesis of prostacylin analogs. The present invention provides an efficient method for synthesizing a Formula I compound.
    Type: Application
    Filed: March 1, 2012
    Publication date: December 26, 2013
    Inventor: Vijay Sharma
  • Publication number: 20130324514
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2, R3, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.
    Type: Application
    Filed: May 22, 2013
    Publication date: December 5, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Dieter HAMPRECHT, Sara FRATTINI, Iain LINGARD, Stefan PETERS
  • Publication number: 20130303798
    Abstract: A production process for substituted phenylacetic acids or ester analogues thereof is disclosed. In this process toluene or toluene substituted with various substituents, an alcohol, an oxidant and carbon monoxide are used as raw materials to obtain compounds comprising structure of phenylacetic acid ester or analogues thereof by catalysis of the complex catalyst formed from transition metal and ligand, and such compounds are hydrolyzed to obtain various substituted phenylacetic acid based compounds. This type of compounds and their derivatives serve as important fine chemicals used widely in the industries of pharmaceuticals, pesticides, perfume and the like.
    Type: Application
    Filed: December 20, 2012
    Publication date: November 14, 2013
    Applicant: Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences
    Inventor: Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences
  • Publication number: 20130289304
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Application
    Filed: July 2, 2013
    Publication date: October 31, 2013
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Publication number: 20130281652
    Abstract: The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same. Ar—[O—(X)p—R?]q??I Polymers formed from the functionalized phenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.
    Type: Application
    Filed: October 17, 2012
    Publication date: October 24, 2013
    Inventor: Rao S. Bezwada
  • Publication number: 20130274240
    Abstract: The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.
    Type: Application
    Filed: November 5, 2012
    Publication date: October 17, 2013
    Inventor: JAPAN TOBACCO INC.
  • Publication number: 20130267734
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Application
    Filed: June 5, 2013
    Publication date: October 10, 2013
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Publication number: 20130261187
    Abstract: This invention pertains generally to prostacyclin analogs and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and methods of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally.
    Type: Application
    Filed: May 31, 2013
    Publication date: October 3, 2013
    Inventors: Ken Phares, David Mottola
  • Publication number: 20130261122
    Abstract: The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
    Type: Application
    Filed: December 16, 2011
    Publication date: October 3, 2013
    Applicant: N30 Pharmaceuticls, Inc.
    Inventors: Xicheng Sun, Jian Qiu, Adam Stout
  • Patent number: 8546392
    Abstract: The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: October 1, 2013
    Assignee: Universitaet des Saarlandes
    Inventors: Rolf Hartmann, Martin Frotscher, Sandrine Oberwinkler, Erika Ziegler, Josef Messinger, Heinrich-Hubert Thole
  • Patent number: 8524939
    Abstract: Novel processes for preparing optically active cyclopentanones 1 which are useful for the preparation of benzindene Prostaglandins and novel cyclopentanones are provided. The invention also provides novel processes of preparing benzindene Prostaglandins and novel intermediates for benzindene Prostaglandins.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: September 3, 2013
    Assignee: Chirogate International Inc.
    Inventors: Shih-Yi Wei, Min-Kuan Hsu, Ming-Kun Hsu
  • Publication number: 20130217768
    Abstract: Processes for preparing water soluble and oil soluble antioxidant compositions extracted together from Labiatae herbs in a single extraction using an alcohol and water solvent, followed by a simple, yet effective purification step that allows the separation of the water soluble antioxidative fractions containing mainly rosmarinic acid from antioxidative fractions containing mainly carnosic acid and carnosol, without cumbersome acid/base partitioning steps.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 22, 2013
    Applicant: KALAMAZOO HOLDINGS, INC.
    Inventors: Roger Nahas, Elizabeth Barren, Gregory S. Reynhout
  • Patent number: 8513456
    Abstract: A carnosic acid-rich plant extract can be produced by extracting a dried and comminuted plant material containing carnosic acid with supercritical CO2 at a pressure of at least 200 bar and at a temperature of at most 100° C. In a first step, supercritical CO2 in a quantity of 10 to 50 kg of CO2 per kg of plant material is passed through the plant material to obtain a first CO2 extract. In a second step, additional supercritical CO2 is passed through the plant material to obtain a second CO2 extract, and a carnosic acid-rich plant extract is separated from the second CO2 extract by lowering the pressure.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: August 20, 2013
    Assignee: Evonik Degussa GmbH
    Inventors: Johann Wiesmueller, Franz Michlbauer, Ralf Kahleyss, Helmut Hausner
  • Publication number: 20130203727
    Abstract: The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).
    Type: Application
    Filed: July 1, 2011
    Publication date: August 8, 2013
    Applicant: GILEAD SCIENCES, INC.
    Inventors: Kerim Babaoglu, Elizabeth Bacon, Kyla Bjornson, Hongyan Guo, Randall L. Halcomb, Paul Hrvatin, John O. Link, Hongtao Liu, Ryan McFadden, Michael L. Mitchell, Paul Roethle, James Taylor, James D. Trenkle, Randall W. Vivian, Lianhong Xu
  • Patent number: 8497393
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: July 30, 2013
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh